Related Experiment Video
Updated: Jan 26, 2026

Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation
Published on: September 7, 2010
The Role of Toll-Like Receptors in Oncotherapy
Caiqi Liu1, Ci Han2, Jinfeng Liu3
1Department of Gastroenterology, Second Affiliated Hospital of Harbin Medical University, Harbin, P.R. China.
Abstract:
Toll-like receptors (TLRs) are associated with tumor growth and immunosuppression, as well as apoptosis and immune system activation. TLRs can activate apoptosis and innate and adaptive immunity pathways, which can be pharmacologically targeted for the development of anticancer oncotherapies. Several studies and clinical trials indicate that TLR agonists are promising adjuvants or elements of novel therapies, particularly when used in conjunction with chemotherapy or radiotherapy. An increasing number of studies suggest that the activation of TLRs in various cancer types is related to oncotherapy; however, before this finding can be applied to clinical practice, additional studies are required. Research suggests that TLR agonists may have potential applications in cancer therapy; nevertheless, because TLR signaling can also promote tumorigenesis, a critical and comprehensive evaluation of TLR action is warranted. This review focuses on recent studies that have assessed the strengths and weaknesses of utilizing TLR agonists as potential anticancer agents.
Insights
Toll-like receptor (TLR) agonists show promise in cancer therapy by activating immune responses and apoptosis. However, their dual role in promoting tumorigenesis requires careful evaluation for safe clinical application.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Toll-like receptors (TLRs) play a dual role in cancer, influencing tumor growth, immunosuppression, apoptosis, and immune activation.
- TLR pathways are pharmacologically targetable for developing novel anticancer oncotherapies.
Purpose of the Study:
- To review recent studies on the strengths and weaknesses of TLR agonists as anticancer agents.
- To critically evaluate the potential and risks of TLR activation in cancer therapy.
Main Methods:
- Literature review of recent studies and clinical trials on TLR agonists in cancer.
- Analysis of TLR signaling pathways in various cancer types.
- Assessment of TLR agonists as adjuvants or components of oncotherapy.
Main Results:
- TLR agonists show potential as adjuvants in chemotherapy and radiotherapy.
- Evidence suggests TLR activation is linked to oncotherapy outcomes in diverse cancers.
- TLR signaling can also contribute to tumorigenesis, necessitating a balanced approach.
Conclusions:
- TLR agonists represent promising candidates for novel cancer therapies.
- Further research is required to optimize TLR-based strategies and mitigate risks.
- A comprehensive evaluation of TLR action is crucial before widespread clinical application.
More Related Videos
Related Concept Videos
Internal Receptors
Receptor-mediated Endocytosis
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
G-protein Coupled Receptors
The Role of Culture

